When three patients die after taking a cutting-edge drug, most companies hit the brakes. Not Sarepta Therapeutics. The ...

Drugmaker Sarepta Therapeutics says it won’t comply with a request from U.S. regulators to halt all shipments of its gene ...

The death comes four months after Sarepta acknowledged the death of a 16-year-old young man with Duchenne muscular dystrophy following treatment with its marketed gene therapy Elevidys® ...